Rocket Pharmaceuticals Inc expected to post earnings of 37 cents a share - Earnings Preview

Rocket Pharmaceuticals

03/08/2026 12:25

Rocket Pharmaceuticals Inc RCKT.OQ RCKT.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026
The Cranbury New Jersey-based  company is expected to report revenue of $20 million, according to the mean estimate from 9 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Rocket Pharmaceuticals Inc is for earnings of 37 cents per share. 
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy," 6 "hold" and 2 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $10.00, about 221.5% above its last closing price of $3.11
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.41
-0.41
-0.42
Missed
-3.2
Dec. 31 2026
-0.48
-0.45
-0.38
Beat
16.2
Sep. 30 2025
-0.51
-0.50
-0.45
Beat
10.9​
Jun. 30 2025
-0.55
-0.56
-0.59
Missed
-6
​​Mar. 31 2025
-0.59
-0.61
-0.56
Beat
8.8
Dec. 31 2024
-0.71
-0.72
-0.62
Beat
13.6​
Sep. 30 2024
-0.75
-0.76
-0.71
Beat
6.6
Jun. 30 2024
-0.71
-0.72
-0.74
Missed
-3.2
This summary was machine generated August 3 at 11:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)